
Reset all filters
01 12Cabometyx
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 349
2019 Revenue in Millions : 293
Growth (%) : 19
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 390
2020 Revenue in Millions : 349
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 481
2021 Revenue in Millions : 390
Growth (%) : 23
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 59
2021 Revenue in Millions : 54
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 577
2022 Revenue in Millions : 481
Growth (%) : 19
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 56
2022 Revenue in Millions : 60
Growth (%) : 5
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 617
2023 Revenue in Millions : 577
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 58
2023 Revenue in Millions : 56
Growth (%) : 4
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 7
2015 Revenue in Millions : Not Reported
Growth (%) : New Launch
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 64
2016 Revenue in Millions : 9
Growth (%) : 618